Summer’s here! It’s time to break out a swim suit, slip on some flip-flops, smother your skin with sunscreen, and relax. We’re still waiting for the clouds to part in the UK (as usual) but when they do plenty will…
We are now three years into the ‘Decade of vision’, a resolution passed by the US Senate to recognise the 40th anniversary of the National Eye Institute (NEI) and back their efforts to prevent blindness and to save and restore…
News that the National Institute for Health and Care Excellence (NICE) has approved the use of Eylea – a further drug to treat wet age-related degeneration (AMD) – has been well received by bodies such as the Royal National Institute for Blind…
Antihypertensives, including angiotensin-converting-enzyme (ACE) inhibitors and beta blockers, may have the additional benefit of lowering the risk of both forms of age-related macular degeneration (AMD), a large retrospective study shows. Dr. Partho Kalyani, a fellow in the Department of Ophthalmology…
Age-related macular degeneration (AMD) is an eyesight condition which develops as people age and is most often seen in people aged over 65, although it is also increasingly developed by those in their 40s and 50s. Left untreated the disease…
Each day it is estimated that 100 people in the UK begin to lose their sight. The Royal National Institute of Blind People (RNIB) is campaigning for over 50s to have their eyesight examined in order to detect the earlier signs of…
Are “westernised” habits affecting Asian eyesight? Weights have soared in Malaysia which is statistically the fattest country in South-East Asia with two in five adults classed as overweight. This has caused a dramatic increase in type 2 diabetes and as…
The long-awaited results of Age-Related Eye Disease Study 2 (AREDS2) have shown that adding omega-3 fatty acids and other nutrients to standard antioxidant vitamins doesn’t give any added protection against age-related macular degeneration (AMD). The disease is reported as the…
On 6th June Elektron Technology Ophthalmic will be showcasing the MPS II macular pigment screener at the Vision Congress in Lisbon. This year’s Vision Congress will see a panel of leading eye care professionals discuss the latest research and insights…
The MPS II macular pigment screener offers fast, reliable results. It gives eye health professionals the ability to detect, treat, and prevent various eye diseases such as age-related macular degeneration (AMD). This is good for the patient, and the MPS…